Today: 9 June 2026
Synopsys stock rises as CEO flags export curbs, points to March Converge event
13 January 2026
2 mins read

Synopsys stock rises as CEO flags export curbs, points to March Converge event

New York, Jan 12, 2026, 21:23 EST — Market closed.

  • Shares of Synopsys climbed 1.6% by Monday’s close
  • In the 2025 shareholder letter, the CEO highlights export restrictions and “execution challenges.”
  • Investors are focused on the Jan. 15 Needham conference, looking for new signs of demand and updates on integration progress

Synopsys (SNPS.O) ended Monday 1.6% higher at $533.42 as investors digested a shareholder letter from CEO Sassine Ghazi. He highlighted “export restrictions” adding “a measure of uncertainty” to 2025 and flagged “execution challenges.” Ghazi also announced the company will showcase its integrated Synopsys-Ansys platform at a “Synopsys Converge” event in Silicon Valley this March. Synopsys Investor Relations

Timing is key. Export restrictions now heavily influence chip tools and design software sectors, with investors scrambling to assess how much disruption is already priced into forecasts for 2026.

Synopsys provides electronic design automation (EDA) software, which engineers rely on to design and verify chips digitally before manufacturing. The company is also ramping up efforts in simulation, a tool that models how products perform in real-world conditions.

Ignite Next announced Monday that Synopsys is now part of its European scale-up program, joining Intel and Infineon as a “focus technology collaborator.” Synopsys Chief Strategy Officer Antonio Varas highlighted the growing impact of nimble deep tech startups on breakthroughs in semiconductors, AI, and advanced computing. PR Newswire

Synopsys wrapped up its acquisition of Ansys in July 2025, stating the move would broaden its addressable market and accelerate an integrated technology roadmap. The company also said combined capabilities are expected to roll out in the first half of 2026, with Ansys shares set to stop trading on Nasdaq.

Synopsys projected fiscal 2026 revenue between $9.56 billion and $9.66 billion in December, with non-GAAP earnings per share expected to land from $14.32 to $14.40. This includes an anticipated $2.9 billion in revenue from Ansys. The non-GAAP numbers leave out items like acquisition-related amortization. The company also noted that these targets assume no additional shifts in export controls or U.S. “Entity List” restrictions.

In December, Nvidia poured $2 billion into Synopsys stock, buying shares at $414.79 each, deepening a partnership centered on GPU-accelerated simulation and “agentic” AI workflows, the companies announced. Nvidia CEO Jensen Huang remarked, “CUDA GPU-accelerated computing is revolutionizing design.”

Tech stocks edged up, with the Invesco QQQ Trust gaining roughly 0.1% and the iShares Semiconductor ETF climbing around 0.5%. Synopsys outperformed them both.

Synopsys is set to present at the 28th Annual Needham Growth Conference on Jan. 15 at 11:15 a.m. Pacific time. The company will stream the webcast on its investor relations page. Investors will be keen to catch any firmer comments on export controls and early updates on how the Ansys integration is progressing.

New U.S. export restrictions or delays in deploying integrated tools could cast doubt on the company’s targets. The stock remains highly reactive to news tied to China.

Synopsys goes head-to-head mainly with Cadence Design Systems in EDA tools, though big industrial software players like Siemens also field competing platforms. Orders in this space often serve as a leading indicator of chip design activity, well ahead of wafer production.

Tuesday’s session centers on whether Monday’s bounce can stick as traders unpack the shareholder letter. The next major event on the calendar is the Needham appearance on Jan. 15, followed by the March Silicon Valley customer event.

Stock Market Today

  • Applied Materials 10-Year Investment Growth: $1000 to $20,312
    June 9, 2026, 10:25 AM EDT. A $1000 investment in Applied Materials (AMAT) made in June 2016 would be worth $20,312.42 as of June 2026, representing a 1,931.24% gain. Applied Materials, based in Santa Clara, California, supplies equipment for semiconductor device manufacturing, flat panel displays and solar PV products. Its business is divided into Semiconductor Systems, Applied Global Services, and Display segments. The company's tools support critical chipmaking processes, including deposition and implantation on silicon wafers. With over 33,000 systems installed globally, it competes mainly with equipment makers like KLAC and LRCX. This significant return highlights the potential rewards of long-term investment in semiconductor capital equipment providers.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA
Previous Story

Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Next Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Go toTop